Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|The Lancet|2021Cited by 1.7k
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Joaquín Martínez‐López et al.|New England Journal of Medicine|2022Cited by 1.2k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas G. Martin, Sundar Jagannath, Saad Z. Usmani et al.|Journal of Clinical Oncology|2022Cited by 647
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple MyelomaDeepu Madduri, Thomas Martin, Jesús G. Berdeja et al.|Blood|2020Cited by 94
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.Jesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|Journal of Clinical Oncology|2020Cited by 78